News Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Delayed Nasdaq Other stock markets 02:09:04 2024-05-21 pm EDT			5-day change	1st Jan Change
0.9037 ^USD	-2.83%		-1.77%	+1.65%

May. 08	Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 05	Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	May. 20	AQ
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	May. 17	AQ
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 08	AQ
Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	Apr. 05	MT
Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating	Apr. 05	MT
ADRs Close Lower; Moatable Inc. Declines 33.3%	Apr. 04	DJ
Syncona notes investee Achilles's annual loss narrows	Apr. 04	AN
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights	Apr. 04	AQ
Achilles Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 04	CI
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	Apr. 04	AQ
Achilles Therapeutics plc Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	Apr. 04	CI
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference	Feb. 05	AQ
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction	Dec. 18	AQ
BofA Securities Downgrades Achilles Therapeutics to Underperform From Buy, Price Target is $0.50	Dec. 14	MT
Syncona notes investee company's quarterly loss	Nov. 14	AN
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights	Nov. 13	AQ
Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	23-09-22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Summary

Filters